Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1998 Feb;59(2):56-9.
doi: 10.4088/jcp.v59n0203.

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study

J K Buitelaar  1 , R J van der Gaag, J van der Hoeven
Affiliations
Clinical Trial

Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study

J K Buitelaar et al. J Clin Psychiatry. 1998 Feb.

Abstract

Background: We evaluated the efficacy and safety of buspirone in the management of anxiety and irritability in children with pervasive developmental disorders (PDD).

Method: Twenty-two subjects, 6 to 17 years old, with DSM-III-R diagnosed PDD-NOS (N = 20) or autistic disorder (N = 2), were included. They were treated with buspirone in dosages ranging from 15 to 45 mg/day in an open-label trial lasting 6 to 8 weeks. Responders continued buspirone treatment and were followed up for up to 12 months.

Results: Nine subjects had a marked therapeutic response and 7 subjects a moderate response on the Clinical Global Impressions (CGI) scale after 6 to 8 weeks of treatment. Side effects were minimal, except for 1 patient who developed abnormal involuntary movements.

Conclusion: These results suggest that buspirone may be useful for treating symptoms of anxiety and irritability in children with PDD.

PubMed Disclaimer

Publication types